for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pacific Biosciences of California

PACB.O

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
35.54
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
153.03
Market Cap (MIL)
777.41
Forward P/E
-7.15
Dividend (Yield %)
--

Next Event

Q4 2019 Pacific Biosciences of California Inc Earnings Release

Latest Developments

More

Illumina Pacific Biosciences Respond To UK CMA's Provisional Findings In Merger Inquiry

Pacific Biosciences Of California Inc Reports Q3 Revenue Of $21.9 Mln

UK CMA's Provisional Conclusion Is Illumina/PacBio Deal To Result In Loss Of Competition

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Industry

Medical Equipment & Supplies

Contact Info

1305 O'brien Drive

+1.650.5218000

https://www.pacb.com/

Executive Leadership

Michael W. Hunkapiller

Chairman of the Board, President, Chief Executive Officer

Susan K. Barnes

Chief Financial Officer, Executive Vice President

James Michael Phillips

Senior Vice President - Research and Development

William W. Ericson

Lead Independent Director

Kathy P. Ordonez

Director

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.830

2017

-0.870

2018

-0.760

2019(E)

-0.710
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.42
Price To Book (MRQ)
15.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
30.47
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-89.48
Return on Equity (TTM)
-69.81

Latest News

Latest News

BRIEF-Pacific Biosciences Posts Favorable Outcome In UK And German Patent Litigation Against Oxford Nanopore

* PACIFIC BIOSCIENCES ANNOUNCES FAVORABLE OUTCOME IN UK AND GERMAN PATENT LITIGATION AGAINST OXFORD NANOPORE

BRIEF-Pacific Biosciences Of California Reports Qtrly Loss Per Share Of $0.20

* PACIFIC BIOSCIENCES OF CALIFORNIA, INC. ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Pacific Biosciences Announces Ten-Unit Sequel System Order For Annoroad

* PACIFIC BIOSCIENCES ANNOUNCES TEN-UNIT SEQUEL SYSTEM ORDER FOR ANNOROAD Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Pacific Biosciences Prevails In Patent Eligibility Ruling

* PACIFIC BIOSCIENCES PREVAILS IN PATENT ELIGIBILITY RULING AGAINST OXFORD NANOPORE

BRIEF-Pacific Biosciences Of California Prices Public Offering

* PACIFIC BIOSCIENCES OF CALIFORNIA, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Pacific Biosciences Of California Announces Proposed Public Offering Of Common Stock

* PACIFIC BIOSCIENCES OF CALIFORNIA, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Pacific Biosciences of California files for mixed shelf of upto $150 mln

* Pacific Biosciences of California Inc files for mixed shelf of upto $150 million - SEC filing Source text: (http://bit.ly/2ulOr9C) Further company coverage:

BRIEF-Pacific Biosciences Of California qtrly net loss per share $0.26

* Pacific Biosciences Of California Inc - total revenue for Q2 of 2017 was $20.1 million, compared to $20.7 million for Q2 of 2016

BRIEF-Pacific Biosciences signs agreement with Novogene to purchase ten sequel systems

* Pacbio announces new agreement with Novogene to purchase ten sequel systems

BRIEF-Pacific Biosciences of California announces pricing of public offering of common stock

* Pacific Biosciences of California announces pricing of public offering of common stock

BRIEF-Pacific Biosciences announces Q4 2016 financial results

* Pacific Biosciences announces fourth quarter 2016 financial results

BRIEF-Novogene to buy ten PacBio sequel systems for DNA sequencing services

* Novogene agrees to buy ten PacBio sequel systems for DNA sequencing services Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up